Drug

D0802 | betamethasone dipropionate

Molecular Formula C28H37FO7
Molecular Weight 504.6
Structure
State solid

D

S

A

H

R

C

S03CA06 Betamethasone and antiinfectives


[S03CA] Corticosteroids and antiinfectives in combination


[S03C] CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION


[S03] OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS


[S] Sensory organs


S03BA03 Betamethasone


[S03BA] Corticosteroids


[S03B] CORTICOSTEROIDS


[S03] OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS


[S] Sensory organs


S02BA07 Betamethasone


[S02BA] Corticosteroids


[S02B] CORTICOSTEROIDS


[S02] OTOLOGICALS


[S] Sensory organs


S01CB04 Betamethasone


[S01CB] Corticosteroids/antiinfectives/mydriatics in combination


[S01C] ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION


[S01] OPHTHALMOLOGICALS


[S] Sensory organs


S01CA05 Betamethasone and antiinfectives


[S01CA] Corticosteroids and antiinfectives in combination


[S01C] ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION


[S01] OPHTHALMOLOGICALS


[S] Sensory organs


S01BB04 Betamethasone and mydriatics


[S01BB] Corticosteroids and mydriatics in combination


[S01B] ANTIINFLAMMATORY AGENTS


[S01] OPHTHALMOLOGICALS


[S] Sensory organs


S01BA06 Betamethasone


[S01BA] Corticosteroids, plain


[S01B] ANTIINFLAMMATORY AGENTS


[S01] OPHTHALMOLOGICALS


[S] Sensory organs


R03BA04 Betamethasone


[R03BA] Glucocorticoids


[R03B] OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS


[R03] DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES


[R] Respiratory system


R01AD06 Betamethasone


[R01AD] Corticosteroids


[R01A] DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE


[R01] NASAL PREPARATIONS


[R] Respiratory system


H02AB01 Betamethasone


[H02AB] Glucocorticoids


[H02A] CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN


[H02] CORTICOSTEROIDS FOR SYSTEMIC USE


[H] Systemic hormonal preparations, excluding reproductive hormones and insulins


D07XC01 Betamethasone


[D07XC] Corticosteroids, potent, other combinations


[D07X] CORTICOSTEROIDS, OTHER COMBINATIONS


[D07] CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS


[D] Dermatological drugs


D07CC01 Betamethasone and antibiotics


[D07CC] Corticosteroids, potent, combinations with antibiotics


[D07C] CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS


[D07] CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS


[D] Dermatological drugs


D07BC01 Betamethasone and antiseptics


[D07BC] Corticosteroids, potent, combinations with antiseptics


[D07B] CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS


[D07] CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS


[D] Dermatological drugs


D07AC01 Betamethasone


[D07AC] Corticosteroids, potent (group III)


[D07A] CORTICOSTEROIDS, PLAIN


[D07] CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS


[D] Dermatological drugs


C05AA05 Betamethasone


[C05AA] Corticosteroids


[C05A] AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE


[C05] VASOPROTECTIVES


[C] Cardiovascular system


A07EA04 Betamethasone


[A07EA] Corticosteroids acting locally


[A07E] INTESTINAL ANTIINFLAMMATORY AGENTS


[A07] ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS


[A] Alimentary tract and metabolism


Toxicity Dose Time Species Model Method Action Positive criterion Reference
MEMBRANE POTENTIAL 25.60±1.67 human qHTS-HepG2 MMP assay decrease IC50 163
MEMBRANE POTENTIAL 19.45 human HepG2 MMP assay decrease IC50 163
MEMBRANE POTENTIAL rat hepatocytes MMP assay Negative IC50 163

Pictogram Signal Statements Precautionary Statement Codes
Danger

Aggregated GHS information provided by 108 companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


Reported as not meeting GHS hazard criteria by 2 of 108 companies. For more detailed information, please visit ECHA C&L website


Of the 9 notification(s) provided by 106 of 108 companies with hazard statement code(s):


H330 (33.02%): Fatal if inhaled [Danger Acute toxicity, inhalation]


H360 (44.34%): May damage fertility or the unborn child [Danger Reproductive toxicity]


H361 (54.72%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]


H372 (42.45%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure]


H410 (42.45%): Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


P201, P202, P260, P264, P270, P271, P273, P281, P284, P304+P340, P308+P313, P310, P314, P320, P391, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Organism Test type Route Dose (normalized dose) Effect Source
rat LD50 subcutaneous > 4gm/kg (4000mg/kg) Shikoku Igaku Zasshi. Shikoku Medical Journal. Vol. 29, Pg. 153, 1973.
rat LD50 intraperitoneal > 4gm/kg (4000mg/kg) Shikoku Igaku Zasshi. Shikoku Medical Journal. Vol. 29, Pg. 153, 1973.
mouse LD50 intraperitoneal 103mg/kg (103mg/kg) Drugs in Japan Vol. 6, Pg. 753, 1982.
rat LD50 oral > 4gm/kg (4000mg/kg) Shikoku Igaku Zasshi. Shikoku Medical Journal. Vol. 29, Pg. 153, 1973.
mouse LD50 subcutaneous 78100ug/kg (78.1mg/kg) Drugs in Japan Vol. 6, Pg. 753, 1982.
mouse LD50 oral > 5gm/kg (5000mg/kg) Shikoku Igaku Zasshi. Shikoku Medical Journal. Vol. 29, Pg. 153, 1973.


  • (11-beta,16-beta)-9-Chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione (11.beta.,16.beta.)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate (11beta,16beta)-9-fluoro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl dipropanoate
    (8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-(2-(propionyloxy)acetyl)-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthr 2-((2S,10S,11S,13S,15S,17S,1R,14R)-1-fluoro-17-hydroxy-2,13,15-trimethyl-5-oxo -14-propanoyloxytetracyclo[8.7.0.0<2,7>.0<11,15>]heptadeca-3,6-dien-14-yl)-2-o xoethyl propanoate 5593-20-4
    826Y60901U 9-Fluoro-11.beta.,17,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate 9-Fluoro-11.beta.-hydroxy-16.beta.-methyl-3,20-dioxo-17-(propionyloxy)pregna-1,4-dien-21-yl propionate #
    9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-di(propionate) 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione-17,21-dipropionate
    9-fluoro-11beta-hydroxy-16beta-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl dipropanoate 9alpha-Fluoro-11beta,17alpha,21-trihydroxy-16beta-methyl-1,4-pregnadiene-3,20-dione 17,21-Dipropionate 9alpha-fluoro-11beta,17alpha,21-trihydroxy-16beta-methyl-3,20-dioxopregna-1,4-diene- 17,21-diyl dipropionate
    AB01274713-01 AB01274713_02 AB2000220
    AKOS015969733 Alphatrex B3166
    BDBM50421892 BETAMETHASONE DIPROP BETAMETHASONE DIPROPIONATE
    BRD-K58148589-001-03-6 BRN 3638108 Beloderm
    Betamethasone 17,21-dipropionate Betamethasone Dipropionate (Diprolene) Betamethasone dipropionate (JP17/USP)
    Betamethasone dipropionate [USAN:BAN:JAN] Betamethasone dipropionate [USAN:USP:JAN] Betamethasone-17,21-dipropionate
    Betamethasone-Dipropionate(Diprolene) C-22966 C28H37FO7
    CAS-5593-20-4 CC-24614 CHEBI:31276
    CHEMBL1200384 CIWBQSYVNNPZIQ-XYWKZLDCSA-N CS-7549
    D01637 DSSTox_CID_2672 DSSTox_GSID_22672
    DSSTox_RID_76683 DTXSID2022672 Diproderm
    Diprolene Diprolene (TN) Diprolene AF
    Diprosis Diprosone Diprospan;Diprolene;Diprosone;Diprolene AF;Diprolene
    EBD2157850 EINECS 227-005-2 HY-13571
    KS-5303 LS-118474 Maxivate
    NCGC00159360-02 NCGC00159443-01 NCGC00159443-02
    Pregna-1,4-diene-3,20-dione, 9-fluoro-11-.beta.,17,21-trihydroxy-16-.beta.-methyl-,17,21-dipropionate Pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,17,21-trihydroxy-16-beta-methyl-, 17,21-dipropionate Pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,17,21-trihydroxy-16-beta-methyl-,17,21-dipropionate;
    Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11.beta.,16.beta.)- Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11beta,16beta) Psorion
    Q4897349 Rinderon DP Rinderon-DP (TN)
    S 3440 S-3440 SCHEMBL7519
    ST024761 Sch 11460 Sch-11460
    Sernivo Sernivo (TN) Tox21_113343
    UNII-826Y60901U ZINC4212137 [2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate
    beta-Methasone 17,21-dipropionate betamethasone dipropionat betamethasone propionate
    component of Alphatrex (Salt/Mix) component of Betasone (Salt/Mix) en-17-yl propionate
    s1688

    DrugBank DB00443
    CAS Number 5593-20-4
    PubChem Compound 21800
    KEGG Drug D01637
    ChEBI 31276